ESNM Webinars

Our webinars give you an opportunity to stay at the forefront of our rapidly evolving field Neurogastroenterology and Motility. Join us to update your knowledge and engage with leaders, experts and the ESNM network.

Webinar Series 2022 on Clostridioides difficile

In a series of 7 webinar this programme will develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches.

The course will be held by a distinguished Faculty with expertise in the fields of neurogastroenterology, functional gastrointestinal disorders and microbiota. Our aim is to promote the dissemination of information and stimulate interesting live discussions that would ultimately improve the healthcare of our patients.

Please note: the official language of the course is English. Simultaneous translation will not be provided. The webinar course is supported with a grant from Ferring Pharmaceutical. The programme of these webinars have been independently developed and approved by the European Society of Neurogastroenterology and Motility (ESNM) and its faculty members.

About this webinar

Clostridioides (previously known as Clostridium) difficile (C. difficile) is a key cause of healthcare-associated infections and poses a substantial public health threat that carries high morbidity and mortality rates, especially amongst affected elderly patients (>65 years). C. difficile infection (CDI) also places a considerable burden on healthcare systems worldwide, with up to one-third of patients who develop an initial episode of CDI subsequently going on to develop a recurrence.

C. difficile bacteria is widely found in the environment, especially in the soil, and in the digestive system of animals and humans. In healthy individuals, a healthy gut microbiota comprising a broad consortium of micro-organisms is able to prevent C. difficile from multiplying to harmful levels in the gut and thus provide resistance against CDI. However, disruption of the composition and/or diversity (i.e. dysbiosis) of the gut microbiota allows proliferation of C. difficile and the subsequent production of toxins that lead to clinical symptoms of CDI, which range from mild diarrhoea through to, in severe and complicated cases, toxic megacolon, and even death. In addition, the diagnosis and management of patients with CDI is often complicated due to the presence of other dysbiosis-associated co-morbidities (e.g. Crohn’s disease and ulcerative colitis), while emerging evidence suggests that there is an increased risk of post-infection irritable bowel syndrome following CDI.

Current clinical guidelines issued by infectious disease and/or gastroenterology societies in the United States and Europe recommend oral antibiotics (vancomycin, metronidazole or fidaxomicin) as first-line therapy for the initial episode of CDI, as well as for first recurrence of CDI, depending on the severity of the condition. While antibiotic treatment of CDI can resolve the infection, it can also maintain the microbiota in a disrupted state; thus, leaving a patient susceptible to recurrence of CDI and, ultimately, leading to a vicious cycle of recurrent disease.

The relationship between CDI and dysbiosis means that treatment approaches should also consider the impact on the gut microbiome. Indeed, this is reflected in clinical guidelines with the inclusion of non-antibiotic treatments, such as fecal microbiota transplantation and monoclonal antibody. In addition, different non-antibiotic modalities, such as antibodies, microbiota-based therapeutics and vaccines, are currently being actively investigated in the prevention or treatment of recurrent CDI.

While there is widespread scientific literature regarding CDI, there is still a need to better inform the wider medical community on the importance of recognising the microbiome-mediated nature of CDI and how different treatment modalities available can help to resolve the condition and/or restore the gut microbiota to avoid recurrence.

The gut microbiota – Tuesday, March 29, 2022

16:00 -17:00hrs (CET)

Chair: René van den Wijngaard, Amsterdam, The Netherlands

Importance of gut microbiota in Clostridioides difficile Infection, Joël Doré, Paris, France
A patient’s perspective on C. difficile, Gail P Attara, Gastrointestinal Society, Vancouver, Canada
Followed by Q&A with all chairs and speakers
 
 
Introduction to Clostridioides difficile infection – April 26, 2022

16:00 -17:00hrs (CEST)

Chair: Edoardo Savarino, Padova, Italy
Epidemiology and outcome of patients with Clostridioides difficile infection, Daniele Roberto Giacobbe, Genoa, Italy
IBD and IBS: “good” patients for bad Clostridioides difficile infection? Harry Sokol , Paris, France
Followed by Q&A with chairs and speakers

In order to join the webinar, please register for the event (free of charge). Once registered you will receive a confirmation email with the dial-in information for the webinar.
Pathogenesis of CDI – May 31, 2022

16:00 -17:00hrs (CEST)

Chair: Joël Doré, Paris, France
C. difficile as a model of dysbiosis: the role of microbiota and microbial metabolites, Ben Mullish, London, UK (rising star UEG 2021)
Overview on Clostridioides difficile infection pathogenesis, Ed Kujiper, Leiden, The Netherlands
Followed by Q&A with chairs and speakers


In order to join the webinar, please register for the event (free of charge). Once registered you will receive a confirmation email with the dial-in information for the webinar.
Clinical picture and testing of CDI – June 28, 2022

16:00 -17:00hrs (CEST)

Chair: Aonghus Lavelle, Cork, Ireland
Clinical features of Clostridioides difficile infection, (TBC)
Clostridioides difficile infection laboratory investigations: When and how, Frédéric Barbut, Paris, France
Followed by Q&A with chair and speakers

In order to join the webinar, please register for the event (free of charge). Once registered you will receive a confirmation email with the dial-in information for the webinar.
Treatment options for CDI – September 06, 2022

16:00 -17:00hrs (CEST)

Chair: Giovanni Barbara, Bologna, Italy
First-line management, Nicola Petrosillo, Rome, Italy
Faecal Microbiota Transplantation (FMT), Gianluca Ianiro, Rome Italy
Followed by Q&A with chairs and speakers

To join us for our webinar series you need to book for the event. Once registered you will receive a confirmation email with dial in details for the webinar. Please note: Registration link follows.

Prevention of recurrence and re-infections – October 12, 2022

16:00 -17:00hrs (CEST)

Chair: Daniel Pohl, Zurich, Switzerland
Management of recurrence of Clostridioides difficile infection, Steven Johnson, Buies Creek, North Carolina, USA
Management of severe Clostridioides difficile infection, Tariq Iqbal, Birmingham, United Kingdom
Followed by Q&A with all chairs and speakers

In order to join the webinar, please register for the event (free of charge). Once registered you will receive a confirmation email with the dial-in information for the webinar. Please note: Registration link follows.

Future perspectives – November 22, 2022

More information to follow

Webinar Faculty

Prof. Qasim Aziz (Speaker & Moderator & Programme Chair)
Professor of Neurogastroenterology at Queen Mary University of London - President of the European Society of Neurogastroenterology and Motility (ESNM) - Member of the United European Gastroenterology Federation Education Committee

Prof. Giovanni Barbara (Speaker & Moderator & Programme Chair)
Professor of Gastroenterology at University of Bologna - Gastroenterologist at Department of Medical and Surgical Sciences St. Orsola-Malpighi Hospital of Bologna - Past President of European Society of Neurogastroenterology and Motility (ESNM) – Chair of the ESNM Section Gut Microbiota and Health

Prof. Joël Doré (Speaker & Moderator & Programme Chair)
Research Director at the French Research Institute in Agricultural Sciences, INRA, Paris - Deputy Head of the MICALIS Institute “Food and Gut Microbiology for Human Health”

Prof. Daniel Pohl (Moderator & Programme Chair)
Professor of Gastroenterology at University Hospital Zurich Division of Gastroenterology and Hepatology – Treasurer of the European Society of Neurogastroenterology and Motility (ESNM)

Prof. Edoardo Savarino (Moderator)
Department of Surgery, Oncology and Gastroenterology - DiSCOG, University of Padova, ITALY

Prof. Harry Sokol (Speaker)
Full Professor of Gastroenterology at Sorbonne University of Paris - Gastroenterologist at Gastroenterology Department, Saint-Antoine Hospital of Paris

Prof. René van den Wijngaard (Moderator)
Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Location AMC, THE NETHERLANDS

Previous videos

On our official YouTube channel you can find previous meetings of our webinar series on C. difficileinfection (CDI).

Copyright 2022